Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-6901
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies ; volume:16 ; number:1 ; day:6 ; month:1 ; year:2016 ; pages:81-92 ; date:3.2016
Drugs in R & D ; 16, Heft 1 (6.1.2016), 81-92, 3.2016
- Urheber
-
Martin, Paul
- Beteiligte Personen und Organisationen
-
Gillen, Michael
Millson, David
Oliver, Stuart
Brealey, Clive
Grossbard, Elliott B.
Baluom, Muhammad
Lau, David
Sweeny, David
Mant, Tim
Craven, Kelli
SpringerLink (Online service)
- DOI
-
10.1007/s40268-015-0118-4
- URN
-
urn:nbn:de:1111-201602271893
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Martin, Paul
- Gillen, Michael
- Millson, David
- Oliver, Stuart
- Brealey, Clive
- Grossbard, Elliott B.
- Baluom, Muhammad
- Lau, David
- Sweeny, David
- Mant, Tim
- Craven, Kelli
- SpringerLink (Online service)
Ähnliche Objekte (12)
CYP3A4 and CYP3A5genotyping by Pyrosequencing
Antivirals and nuclear receptor activation of CYP3A4 and 2B6
Myricetin inhibits CYP3A4, GST, and MRP1 in hepatic cancer cells
CYP3A4 drug metabolism considerations in pediatric pharmacotherapy
Individualizing simvastatin dose with respect to CYP3A4 activity
Polymorphismen in der Promoter- und Enhancerregion von CYP3A4
Genetic variability in CYP3A4 and CYP3A5in primary liver, gastric and colorectal cancer patients
Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4
MicroRNA regulation of CYP 1A2, CYP3A4 and CYP2E1 expression in acetaminophen toxicity
Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients
CYP3A4 and CYP3A5genotyping by Pyrosequencing
Antivirals and nuclear receptor activation of CYP3A4 and 2B6
Myricetin inhibits CYP3A4, GST, and MRP1 in hepatic cancer cells
CYP3A4 drug metabolism considerations in pediatric pharmacotherapy
Individualizing simvastatin dose with respect to CYP3A4 activity
Polymorphismen in der Promoter- und Enhancerregion von CYP3A4
Genetic variability in CYP3A4 and CYP3A5in primary liver, gastric and colorectal cancer patients
Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4
MicroRNA regulation of CYP 1A2, CYP3A4 and CYP2E1 expression in acetaminophen toxicity
Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients
CYP3A4 and CYP3A5genotyping by Pyrosequencing
Antivirals and nuclear receptor activation of CYP3A4 and 2B6
Myricetin inhibits CYP3A4, GST, and MRP1 in hepatic cancer cells
CYP3A4 drug metabolism considerations in pediatric pharmacotherapy
Individualizing simvastatin dose with respect to CYP3A4 activity
Polymorphismen in der Promoter- und Enhancerregion von CYP3A4
Genetic variability in CYP3A4 and CYP3A5in primary liver, gastric and colorectal cancer patients
Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4
MicroRNA regulation of CYP 1A2, CYP3A4 and CYP2E1 expression in acetaminophen toxicity
Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism